{"id":608505,"date":"2026-08-14T22:36:33","date_gmt":"2026-08-14T22:36:33","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/608505\/ibogaine-by-david-dardashti-proposes-medical-offramp-for-displaced-kratom-users-amid-global-bans-urges-expansion-of-right-to-try-policy.html"},"modified":"2026-08-14T22:36:33","modified_gmt":"2026-08-14T22:36:33","slug":"ibogaine-by-david-dardashti-proposes-medical-offramp-for-displaced-kratom-users-amid-global-bans-urges-expansion-of-right-to-try-policy","status":"publish","type":"post","link":"https:\/\/www.olympiajournal.com\/news\/story\/608505\/ibogaine-by-david-dardashti-proposes-medical-offramp-for-displaced-kratom-users-amid-global-bans-urges-expansion-of-right-to-try-policy.html","title":{"rendered":"Ibogaine by David Dardashti Proposes Medical Off-Ramp for Displaced Kratom Users Amid Global Bans, Urges Expansion of Right to Try Policy"},"content":{"rendered":"
\"Ibogaine<\/a><\/div>\n
Ibogaine by David Dardashti Proposes Medical Off-Ramp for Displaced Kratom Users Amid Global Bans, Urges Expansion of Right to Try Policy<\/div>\n

PLAYA DEL CARMEN, Mexico – August 14, 2026 –<\/strong> As expanding state bans and federal enforcement actions sweep across the United States—restricting access to kratom and concentrated 7-hydroxymitragynine (7-OH) extracts—thousands of daily users face acute withdrawal and sudden dependency crises. In response, Ibogaine by David Dardashti has announced specialized treatment protocols designed to serve as a rapid, medical exit strategy.<\/p>\n

Rather than steering displaced individuals toward long-term Medication-Assisted Treatment (MAT)—swapping a daily herbal habit for multi-year synthetic opioid dependence—Dardashti’s approach utilizes ibogaine to reset central nervous system receptors. By clearing alkaloid binding sites in a single therapeutic window, the treatment eliminates physical cravings without forcing patients into secondary pharmaceutical dependencies.<\/p>\n

To safely process the multi-alkaloid profile unique to kratom, the clinic employs proprietary mathematical modeling software. This system calculates a patient’s total alkaloid exposure against biological variables to determine exact washout periods and customized ibogaine dosing under continuous cardiac monitoring, advancing the treatment from generic application to data-driven precision medicine.<\/p>\n

Concurrently, David Dardashti is championing the expansion of “Right to Try” policy frameworks in the United States, advocating for treatment-resistant patients to access regulated ibogaine therapy stateside. This campaign aligns with established medical policies among key U.S. allies:<\/p>\n